Efficacy and Safety Clinical Trial
Official title:
A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC.
JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2. The purpose of this study is to studying neoadjuvant JS001, or JS001 in combination with pemetrexed and carboplatin to see how well it works in treating patients with resectable NSCLC.
Surgery in combination with preoperative or postoperative chemotherapy is the recommended therapeutic approach for patients with resectable non-small cell lung cancer (NSCLC). However, the prognosis of early-stage NSCLC remains to be improved, with 5-year survival rates ranging from 50% for stage IA to 20% for stage IIIA. Antibodies that block the PD-1 protein have provided a major treatment advance in patients with cancer. JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which has shown its efficacy in the treatment of a variety of malignancies. This study is to studying neoadjuvant JS001, or JS001 in combination with chemotherapy to see how well it works in treating patients with resectable NSCLC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04759534 -
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Not yet recruiting |
NCT05532111 -
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
|
N/A | |
| Active, not recruiting |
NCT04284215 -
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
|
N/A | |
| Completed |
NCT06202456 -
A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
|
Phase 4 | |
| Completed |
NCT04870606 -
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
|
Phase 3 | |
| Completed |
NCT03660761 -
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03794778 -
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
|
Phase 4 | |
| Recruiting |
NCT03255343 -
Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim
|
N/A | |
| Recruiting |
NCT04197544 -
Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.
|
N/A | |
| Recruiting |
NCT04518501 -
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03779776 -
The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants
|
N/A | |
| Not yet recruiting |
NCT06218004 -
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Enrolling by invitation |
NCT02809079 -
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
|
Phase 4 | |
| Recruiting |
NCT06194188 -
A Phase 2 Clinical Study of CU-20401
|
Phase 2 | |
| Recruiting |
NCT03901235 -
MSC Intratissular Injection in Crohn Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03826004 -
Clemastine in Cardiovascular Surgery
|
N/A | |
| Recruiting |
NCT04078399 -
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence
|
N/A | |
| Not yet recruiting |
NCT06383078 -
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
|
Phase 2 | |
| Withdrawn |
NCT05481775 -
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
|
Phase 2 |